The Journal of Immunology, Vol 135, Issue 1 242-246, Copyright © 1985 by American Association of Immunologists

ARTICLES

Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes

EK Main, LA Lampson, MK Hart, J Kornbluth and DB Wilson

The susceptibility of human neuroblastoma cells to direct cellular cytotoxicity has not been previously established. This is of particular interest because of their aggressive growth and low HLA expression. Neuroblastoma lines CHP 100 and CHP 126 were found to be excellent targets in 4-hr CML assays. Natural killer (NK) cells from fresh PBL and from an NK clone, 3.3, have high lytic activity against both cell lines. We also studied mixed lymphocyte culture-generated cytotoxic lines containing allo-specific cytotoxic T lymphocytes (CTL) directed against HLA antigens present on the neuroblastoma target cell lines. These lines did show excellent lytic activity, but cold target competition studies indicated that all of the lysis resulted from NK activity. This was verified by using inhibition studies with the use of monoclonal antibodies. OKT 3 and anti-HLA antibodies that block CTL function caused no reduction in kill. In contrast, anti-lymphocyte function antigen-1 (anti-LFA-1), which blocks both NK and CTL function, significantly inhibited lysis. These results serve as a functional confirmation of earlier findings of a very weak expression of HLA-A,B,C and beta 2-microglobulin on neuroblastoma cells.

This article has been cited by other articles:

				C. M. Coughlin, M. D. Fleming, R. G. Carroll, B. R. Pawel, M. D. Hogarty, X. Shan, B. A. Vance, J. N. Cohen, S. Jairaj, E. M. Lord, et al. Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma J. Clin. Oncol., December 20, 2006; 24(36): 5725 - 5734. [Abstract] [Full Text] [PDF]

				C. M. Coughlin, B. A. Vance, S. A. Grupp, and R. H. Vonderheide RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy Blood, March 15, 2004; 103(6): 2046 - 2054. [Abstract] [Full Text] [PDF]

				R. F. Rousseau, A. E. Haight, C. Hirschmann-Jax, E. S. Yvon, D. R. Rill, Z. Mei, S. C. Smith, S. Inman, K. Cooper, P. Alcoser, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma Blood, March 1, 2003; 101(5): 1718 - 1726. [Abstract] [Full Text] [PDF]

				L. S. Metelitsa, O. V. Naidenko, A. Kant, H.-W. Wu, M. J. Loza, B. Perussia, M. Kronenberg, and R. C. Seeger Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells J. Immunol., September 15, 2001; 167(6): 3114 - 3122. [Abstract] [Full Text] [PDF]

				A. K. Sarkar and J. G. Nuchtern Lysis of MYCN-amplified Neuroblastoma Cells by MYCN Peptide-specific Cytotoxic T Lymphocytes Cancer Res., April 1, 2000; 60(7): 1908 - 1913. [Abstract] [Full Text]

				A. F. Carpentier, L. Chen, F. Maltonti, and J.-Y. Delattre Oligodeoxynucleotides Containing CpG Motifs Can Induce Rejection of a Neuroblastoma in Mice Cancer Res., November 1, 1999; 59(21): 5429 - 5432. [Abstract] [Full Text] [PDF]

				L. Bowman, M. Grossmann, D. Rill, M. Brown, W.-y. Zhong, B. Alexander, T. Leimig, E. Coustan-Smith, D. Campana, J. Jenkins, et al. IL-2 Adenovector-Transduced Autologous Tumor Cells Induce Antitumor Immune Responses in Patients With Neuroblastoma Blood, September 15, 1998; 92(6): 1941 - 1949. [Abstract] [Full Text] [PDF]